This website is for UK Healthcare Professionals only

Superior efficacy in psoriasis with fewer injections vs. secukinumab at 52 Weeks2,3

87% of SKYRIZI patients achieved PASI 90 at Week 52 after 5 doses compared with 57% of secukinumab patients after 16 doses†2,3

Adapted from Warren et al. 2020

Data from IMMerge, a phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded active-comparator study in adult patients with moderate to severe plaque psoriasis.
NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index. P-values for comparison vs secukinumab: *P<0.001 multiplicity controlled.
Data assessed for intent-to-treat population. Adjusted difference CI values: 96.25% at Week 16 and 95%; P values calculated from the Cochran-Mantel-Haenszel test, stratified by weight (≤100 kg vs >100 kg) and prior systemic biologic use for psoriasis.
Each dose for SKYRIZI given as two 75-mg subcutaneous injections, each dose for secukinumab given as two 150-mg subcutaneous injections.
SKYRIZI demonstrated superiority at Week 52 across primary and all ranked secondary endpoints.
Co-primary endpoints were met:

  • Non-inferiority of SKYRIZI vs secukinumab at Week 16 (PASI 90: 74% vs 66%)
  • Superiority of SKYRIZI vs secukinumab at Week 52 (PASI 90: 87% vs 57%, P<0.001)

66% of SKYRIZI patients achieved PASI 100 at Week 52 after 5 doses compared with 40% of secukinumab patients after 16 doses†2,3

Adapted from Warren et al. 2020

Data from IMMerge, a phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded active-comparator study in adult patients with moderate to severe plaque psoriasis.
NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index. P-values for comparison vs secukinumab: *P<0.001 multiplicity controlled.
Data assessed for intent-to-treat population. Adjusted difference CI set at 95%; P values calculated from the Cochran-Mantel-Haenszel test, stratified by weight (≤100 kg vs >100 kg) and prior systemic biologic use for psoriasis.
Each dose for SKYRIZI given as two 75-mg subcutaneous injections, each dose for secukinumab given as two 150-mg subcutaneous injections.
All ranked secondary endpoints were met, including statistically significant superiority of SKYRIZI vs secukinumab at Week 52 (PASI 100: 66% vs 40%, P<0.001). Co-primary endpoints were met: PASI 90 at Week 16 (non-inferiority) and PASI 90 at Week 52 (superiority)


SKYRIZI efficacy vs ustekinumab in
psoriasis4-6

SKYRIZI efficacy vs secukinmab in psoriasis2,3

SKYRIZI efficacy vs adalimumab in
psoriasis7

References

  1. SKYRIZI: Summary of Product Characteristics.
  2. Warren RB et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
  3. Risankizumab versus secukinumab for subjects with moderate to severe plaque psoriasis. ClinicalTrials.gov identifier: NCT03478787. Updated September 20, 2019. Accessed March 2, 2020. https://clinicaltrials.gov/ct2/show/NCT03478787.
  4. Strober B, et al. Poster 1714, presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress, 9-13 October 2019, Madrid, Spain.
  5. Lebwohl MD et al. Integrated analysis of UltIMMa 1&2. Poster presented at ADD March 2019 P8108.
  6. Gordon KB et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018;392: 650-661.
  7. Reich K et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394: 576-586.

UK-RISN-220213. Date of preparation: July 2022. 


SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com